Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -0.3% | -7.4% | -18.1% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 45.7% | 53.9% | 54.9% | 67.3% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£0 | £0 | -£0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -53.6% | -63.9% | -58.5% | -17.9% |
| Other Income/Exp. Net | -£0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | £0 | £0 | £0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -72.9% | -72.9% | -72.3% | -18.9% |
| EPS | -0.008 | -0.011 | -0.064 | -0.021 |
| % Growth | 21.5% | 83.4% | -200.5% | – |
| EPS Diluted | -0.008 | -0.011 | -0.064 | -0.021 |
| Weighted Avg Shares Out | 5 | 4 | 1 | 1 |
| Weighted Avg Shares Out Dil | 5 | 4 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -53.5% | -55.7% | -60.8% | -11.9% |